SpringWorks Therapeutics, Inc.
Clinical trials sponsored by SpringWorks Therapeutics, Inc., explained in plain language.
A biopharmaceutical company developing targeted therapies for rare diseases and cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Liver function and drug breakdown: a new study on mirdametinib Results expected Oct 2026 (estimated)
- New pill targets Hard-to-Treat cancers with hippo pathway mutations Results expected Jan 2027 (estimated)
- New pill shows promise for rare tumor in japanese patients Results expected May 2027 (estimated)
-
New pill shows promise for rare tumor in japanese patients
Disease control OngoingThis phase 2 study tests the drug nirogacestat in 20 Japanese adults with desmoid tumors that are growing. The goal is to see if the drug can shrink tumors or stop them from getting worse. Participants take nirogacestat as an oral tablet, and researchers will monitor tumor respon…
Phase 2 • Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug shows promise for shrinking painful NF1 tumors
Disease control OngoingThis study tests a drug called mirdametinib in 114 adults and children with a genetic condition called NF1 that causes nerve tumors (plexiform neurofibromas) that cannot be removed by surgery and cause serious problems. The drug works by blocking a protein that helps tumors grow.…
Phase 2 • Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC